DFTX (DFTX)
43.67
-1.41 (3.13%)
Upcoming Events
Latest Headlines
Definium Therapeutics Announces New Employee Inducement Grants
July 20, 2026 4:01 PM - BizWire
Definium Therapeutics launches GAD education program for providers
July 16, 2026 7:01 AM - StreetInsider
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
July 16, 2026 7:00 AM - BizWire
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
July 14, 2026 7:00 AM - BizWire
Definium Therapeutics Inc (DFTX) PT Raised to $60 at Stifel
July 7, 2026 4:32 PM - StreetInsider
Definium Therapeutics Announces New Employee Inducement Grants
July 6, 2026 4:01 PM - BizWire
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026 9:00 AM - StreetInsider
Definium Therapeutics Inc (DFTX) PT Lowered to $58 at Canaccord
June 30, 2026 6:42 AM - StreetInsider
Form 4 Definium Therapeutics, For: Jun 25 Filed by: Sullivan Mark
June 26, 2026 4:30 PM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 25 Filed by: Roberts Brandi
June 26, 2026 4:30 PM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 25 Filed by: Barrow Robert
June 26, 2026 4:30 PM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 25 Filed by: Wiley Matthew T.
June 26, 2026 4:30 PM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 25 Filed by: Karlin Daniel
June 26, 2026 4:30 PM - SEC Filing
Definium Therapeutics raises $805M in upsized public offering
June 25, 2026 4:15 PM - StreetInsider
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 25, 2026 4:15 PM - BizWire
Form 144 Definium Therapeutics, Filed by: Sullivan Mark
June 25, 2026 4:10 PM - SEC Filing
Form 144 Definium Therapeutics, Filed by: Wiley Matthew T.
June 25, 2026 4:10 PM - SEC Filing
Form 144 Definium Therapeutics, Filed by: Roberts Brandi
June 25, 2026 4:08 PM - SEC Filing
Form 144 Definium Therapeutics, Filed by: Karlin Daniel
June 25, 2026 4:07 PM - SEC Filing
Form 144 Definium Therapeutics, Filed by: Barrow Robert
June 25, 2026 4:07 PM - SEC Filing
Form 8-K Definium Therapeutics, For: Jun 22
June 24, 2026 5:15 PM - SEC Filing
Form 424B5 Definium Therapeutics,
June 24, 2026 5:10 PM - SEC Filing
Definium Therapeutics prices $700M public offering at $34 per share
June 23, 2026 9:57 PM - StreetInsider
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
June 23, 2026 9:57 PM - BizWire
Definium Therapeutics Inc (DFTX) PT Raised to $74 at Jones Trading
June 23, 2026 8:04 AM - StreetInsider
Definium Therapeutics Inc (DFTX) PT Raised to $50 at Needham
June 23, 2026 7:23 AM - StreetInsider
Definium Therapeutics Inc (DFTX) PT Raised to $57 at Baird
June 23, 2026 6:19 AM - StreetInsider
Form 424B5 Definium Therapeutics,
June 22, 2026 4:18 PM - SEC Filing
Definium Therapeutics plans $500M public share offering
June 22, 2026 4:01 PM - StreetInsider
Definium Therapeutics, Inc. Announces Proposed Public Offering
June 22, 2026 4:01 PM - BizWire
Definium Therapeutics Inc (DFTX) PT Raised to $60 at Oppenheimer
June 22, 2026 11:31 AM - StreetInsider
Definium Therapeutics Inc (DFTX) PT Raised to $52 at Leerink
June 22, 2026 10:20 AM - StreetInsider
Form 4 Definium Therapeutics, For: Jun 22 Filed by: Wiley Matthew T.
June 22, 2026 9:45 AM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 22 Filed by: Karlin Daniel
June 22, 2026 9:45 AM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 22 Filed by: Sullivan Mark
June 22, 2026 9:45 AM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 22 Filed by: Barrow Robert
June 22, 2026 9:45 AM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 22 Filed by: Roberts Brandi
June 22, 2026 9:45 AM - SEC Filing
Form 8-K Definium Therapeutics, For: Jun 22
June 22, 2026 8:03 AM - SEC Filing
Definium's LSD-based pill meets Phase 3 endpoints for depression
June 22, 2026 7:00 AM - StreetInsider
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
June 22, 2026 7:00 AM - BizWire
Definium Therapeutics to release Phase 3 MDD study results June 22
June 21, 2026 5:00 PM - StreetInsider
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
June 21, 2026 5:00 PM - BizWire
Form S-8 Definium Therapeutics,
June 16, 2026 4:07 PM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 11 Filed by: GRYSKA DAVID W
June 15, 2026 4:31 PM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 11 Filed by: CRYSTAL ROGER
June 15, 2026 4:31 PM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 11 Filed by: Vallone Carol A
June 15, 2026 4:30 PM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 11 Filed by: Krebs Andreas
June 15, 2026 4:30 PM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 11 Filed by: Adsett Roger
June 15, 2026 4:30 PM - SEC Filing
Form 4 Definium Therapeutics, For: Jun 11 Filed by: Bruhn Suzanne Louise
June 15, 2026 4:30 PM - SEC Filing
Definium Therapeutics Announces New Employee Inducement Grants
June 15, 2026 4:01 PM - BizWire
Form 8-K Definium Therapeutics, For: Jun 11
June 12, 2026 4:30 PM - SEC Filing
Definium Therapeutics Announces New Employee Inducement Grants
June 1, 2026 4:01 PM - BizWire
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 21, 2026 7:00 AM - BizWire
Form 8-K Definium Therapeutics, For: May 19
May 19, 2026 7:31 AM - SEC Filing
Form SCHEDULE 13G/A Definium Therapeutics, Filed by: Deep Track Capital, LP
May 15, 2026 9:15 AM - SEC Filing
Form 8-K Definium Therapeutics, For: May 12
May 12, 2026 8:15 AM - SEC Filing
Definium begins second phase 3 trial of DT120 for depression
May 12, 2026 7:00 AM - StreetInsider
Definium begins second phase 3 study of DT120 for depression
May 12, 2026 7:00 AM - StreetInsider
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
May 12, 2026 7:00 AM - BizWire
Definium Therapeutics Announces New Employee Inducement Grants
May 11, 2026 4:01 PM - BizWire
Definium Therapeutics Inc (DFTX) PT Lowered to $48 at Piper Sandler
May 8, 2026 7:57 AM - StreetInsider
RBC Capital Reiterates Outperform Rating on Definium Therapeutics Inc (DFTX), sees favorable set up
May 8, 2026 6:32 AM - StreetInsider
Definium Therapeutics, Inc. (DFTX) Misses Q1 EPS by 23c
May 7, 2026 4:20 PM - StreetInsider
Form 10-Q Definium Therapeutics, For: Mar 31
May 7, 2026 4:20 PM - SEC Filing
Form 8-K Definium Therapeutics, For: May 07
May 7, 2026 4:14 PM - SEC Filing
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 7, 2026 4:01 PM - BizWire
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026 4:01 PM - BizWire
Form DEFA14A Definium Therapeutics,
April 27, 2026 4:08 PM - SEC Filing
Form DEF 14A Definium Therapeutics, For: Jun 11
April 27, 2026 4:06 PM - SEC Filing
Definium Therapeutics (DFTX) Reiterated at Buy by Stifel After Analyst Day
April 24, 2026 8:03 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Definium Therapeutics Inc (DFTX)
April 24, 2026 6:41 AM - StreetInsider
Piper Sandler Reiterates Overweight Rating on Definium Therapeutics Inc (DFTX)
April 23, 2026 9:15 AM - StreetInsider
Definium Therapeutics Inc (DFTX) PT Raised to $40 at Oppenheimer
April 23, 2026 8:22 AM - StreetInsider
Full Article List
